ACHC

ACADIA HEALTHCARE COMPANY INC

Healthcare | Mid Cap

$0.33

EPS Forecast

$833

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-07-13

Acadia Healthcare Q1 2026: Revenue Rises, Beds Grow, and Guidances Get Raised

Snapshot: ACHC posts revenue growth and mixed earnings signals

In its first quarter of 2026, Acadia Healthcare Company, Inc. (ticker: ACHC) reported revenue of $828.8 million, up 7.6% from the prior-year period. The increase reflects stronger same-facility performance—revenue up 7.3% with per-patient-day revenue up 5.6% and patient days rising 1.6%. On the bottom line, GAAP earnings per diluted share came in at $0.05, down from $0.09 in the year-ago quarter, while adjusted earnings per diluted share were $0.37, versus $0.40 in the prior year. The earnings numbers reinforce a familiar tension: revenue momentum and EBITDA strength, but GAAP EPS softness that invites a closer look at the mix of non-GAAP adjustments.

From an investor-relations lens, the press release highlights a growth story built on patient volumes and capacity expansion. The company adds 82 newly licensed beds in the quarter—42 beds added to existing facilities and 40 beds from newly constructed facilities—pointing to continued capacity investments intended to drive future revenue growth.

Operational highlights: volumes, mix, and capital deployment

The quarter’s beat on revenue came alongside a steady lift in operating leverage as Acadia emphasizes strong patient volumes across its Acute and RTC (residential treatment center) segments. The company notes that the same-facility revenue growth was supported by higher revenue per patient day and a modest uptick in patient days, underscoring both pricing/mix benefits and volume growth. The 82-bed addition signals ongoing pipeline development and a commitment to expanding capacity to meet demand for behavioral health and substance-use treatment services.

Non-GAAP framing and the guidance lift

Management cautions that Adjusted net income, Adjusted EBITDA, and Adjusted earnings per diluted share are non-GAAP metrics, with a reconciliation beginning on page 10 of the release. Those figures rose in absolute terms versus the prior year for EBITDA (Adjusted EBITDA of $144.2 million vs. $134.2 million), even as GAAP earnings per diluted share declined. This contrast often fuels discussions about earnings surprises and how investors interpret “earnings” depending on whether they focus on GAAP or non-GAAP measures. Notably, the company also stated that it increased its full-year 2026 guidance for Adjusted EBITDA and Adjusted EPS, a move that management framed as reflecting better-than-expected first-quarter performance and ongoing operating efficiencies.

Management voice and the road ahead

In a tone that blends optimism with disciplined execution, CEO Debbie Osteen emphasized that the year’s start reflects strong patient volumes and continued operating efficiencies across Acadia. She suggested that the team is positioned to sustain performance and create long-term value, a reassuring message to investors looking for durability beyond a single quarter. Her remarks imply a belief that the behavioral-health service mix, occupancy dynamics, and incremental bed additions should translate into a higher trajectory for EBITDA and adjusted earnings through 2026.

What this means for ACHC and its peers

For Acadia itself, the Q1 results point to a constructive setup: revenue growth supported by volume and pricing, a solid EBITDA foundation, and a deliberate expansion program that increases capacity in line with demand. The GAAP EPS softness juxtaposed with stronger EBITDA and non-GAAP earnings signals a common industry narrative where visibility into non-GAAP metrics can outpace the strict GAAP accounting view. In the near term, investors will likely parse whether the lifted guidance translates into durable margin expansion as Acadia leverages its expanded bed base and continued efficiency programs.

Among sector peers, the combination of rising demand for behavioral health services, capacity additions, and a focus on operating efficiency may yield a broader re-rating of peers that can demonstrate both top-line growth and a credible path to EBITDA expansion. The emphasis on bed additions suggests a capital-intensive growth model; how financing and utilization costs evolve could influence peer valuations, capital allocation strategies, and potential M&A activity in the space.

Conclusion: a Q1 that compounds into a narrative about growth and discipline

Acadia’s first quarter shows revenue momentum and EBITDA strength, held against a backdrop of GAAP EPS that declined versus a year earlier. The 82-bed expansion, together with a cushion of non-GAAP adjustments, frames a story where management is signaling confidence in the ability to scale operations and improve profitability on an adjusted basis. For investors tracking ACHC, the initial data points—revenue growth, capacity expansion, and a raised guidance target—offer a constructive tilt toward the stock’s earnings narrative, even as the GAAP line invites scrutiny and a closer look at EPS consensus assumptions and the durability of the revenue forecast as the year unfolds.

Keywords: ACHC, EPS, earnings surprise, EPS consensus, revenue forecast, Adjusted EBITDA, Adjusted EPS, non-GAAP, first quarter 2026.